Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: The randomised phase I/II POSEIDON trial

E. Élez, I. Kocáková, T. Höhler, U. M. Martens, C. Bokemeyer, E. Van cutsem, B. Melichar, M. Smakal, T. Csoszi, E. Topuzov, R. Orlova, S. Tjulandin, F. Rivera, J. Straub, R. Bruns, S. Quaratino, Josep Tabernero

Research output: Contribution to journalArticleResearchpeer-review

61 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: The randomised phase I/II POSEIDON trial'. Together they form a unique fingerprint.

Medicine & Life Sciences